Significance of serum and hepatic micro RNA‐122 levels in patients with non‐alcoholic fatty liver disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background & Aims: Non‐alcoholic fatty liver disease (NAFLD) is believed to be a type of metabolic syndrome. Micro RNA‐122 (miR‐122) is the most abundant micro RNA in the liver and is an important factor for the metabolism of glucose and lipids. In the present study, we examined the correlation between the hepatic and serum miR‐122 expression levels and the clinicopathological factors of patients with NAFLD. Methods: We extracted the total RNA, along with preserved mi RNA s, from liver biopsy samples of 67 patients with NAFLD. In 52 of these 67 patients, the total RNA was extracted from serum. The miR‐122 that was obtained by quantitative reverse transcription‐polymerase chain reaction was quantified using TaqMan Micro RNA assays. Results: A significant correlation was detected between serum and hepatic miR‐122 expression (correlation coefficient, 0.461; P = 0.005). Patients with mild steatosis (<33%) showed significantly lower levels of hepatic miR‐122 compared with patients with severe steatosis (>33%) (hepatic miR‐122: mild/severe = 2.158 ± 1.786/4.836 ± 7.506, P = 0.0473; serum miR‐122: mild/severe = 0.002 ± 0.005/0.007 ± 0.001, P = 0.0491). Moreover, hepatic and serum miR‐122 levels were significantly higher in patients with mild fibrosis than in those with severe fibrosis (hepatic miR‐122: mild/severe = 5.201 ± 7.275/2.394 ± 1.547, P = 0.0087; serum miR‐122: mild/severe = 0.008 ± 0.011/0.002 ± 0.004, P = 0.0191). Conclusions: We found that the hepatic and serum miR‐122 levels were associated with hepatic steatosis and fibrosis. The serum miR‐122 level can be a useful predictive marker of liver fibrosis in patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“Inflammation was scored on a scale of 0–9 according to the standards proposed by the Nonalcoholic Steatohepatitis Clinical Research Network (26).”
MethodPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 3×
“miR122 is a key factor of lipid metabolism (23, 24).”
BackgroundPowell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Cited by
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Deiuliis, J. A. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.170 · Cited by 349
Long, J.-K., Dai, W., Zheng, Y.-W., & Zhao, S.-P. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0085-2 · Cited by 281
The clinical potential of circulating microRNAs in obesity
Ji, C., & Guo, X. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0260-0 · Cited by 257
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“For example, some mouse models of NAFLD have shown that upregulation of miR-34a and downregulation of let-7d (a microRNA precursor) decreases FAO, whereas miR-122 promotes steatosis and fibrosis 140 .”
Background
Metadata
- Authors
- Miyaaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., Milazzo, M., Fornari, F., Gramantieri, L., Bolondi, L., & Nakao, K.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2014-01-07
- Volume
- 34
- Issue
- 7
- Pages
- e302-7
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2134896806
- Cited by
- 147
- References
- 6
- FWCI
- 8.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significance of serum and hepatic micro RNA‐122 levels in patients with non‐alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1111/liv.12429
- The paper
- Miyaaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., Milazzo, M., Fornari, F., Gramantieri, L., Bolondi, L., & Nakao, K. (2014). Significance of serum and hepatic micro RNA‐122 levels in patients with non‐alcoholic fatty liver disease. Liver International. https://doi.org/10.1111/liv.12429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.